BCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics)

N/A

Report date: 2024/08/14 09:00:14

Base Information

Drug NameBCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics)
Drug Alias NameChimeric antigen receptor modified T cell injections targeting BCMA (PersonGen BioTherapeutics)UTAA17
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-cell maturation protein inhibitors
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A